Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
Will the recent negative trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Esperion's Q2 Loss Narrows, Revenues Soar Year Over Year Esperion incurred a loss of 5 cents per share for the second quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 15 cents. The company had incurred a loss of 46 cents per share in the year-ago quarter. Esperion generated revenues of $73.8 million, up nearly 186% year over year, driven by higher collaboration revenues and product revenues in the United States. The reported figure beat the Zacks Consensus Estimate of $52 million. Quarter in Detail Esperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet. The company records royalties on sales of i
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]Yahoo! Finance
- Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]Yahoo! Finance
- Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- ESPR's page on the SEC website